Show simple item record

dc.contributor.authorKuhnl, A
dc.contributor.authorPeckitt, C
dc.contributor.authorPatel, B
dc.contributor.authorArdeshna, KM
dc.contributor.authorMacheta, MP
dc.contributor.authorRadford, John A
dc.contributor.authorRod, J
dc.contributor.authorPaneesha, S
dc.contributor.authorBarton, S
dc.contributor.authorChau, I
dc.contributor.authorBegum, R
dc.contributor.authorValeri, N
dc.contributor.authorWotherspoon, A
dc.contributor.authorDu, Y
dc.contributor.authorZerizer, I
dc.contributor.authorCunningham, D
dc.date.accessioned2020-01-29T15:17:43Z
dc.date.available2020-01-29T15:17:43Z
dc.date.issued2019en
dc.identifier.citationKuhnl A, Peckitt C, Patel B, Ardeshna KM, Macheta MP, Radford J, et al. R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Ann Hematol. 2020;99(1):105-12.en
dc.identifier.pmid31776726en
dc.identifier.doi10.1007/s00277-019-03842-4en
dc.identifier.urihttp://hdl.handle.net/10541/622632
dc.description.abstractOutcome of patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) remains poor, highlighting the need for novel treatment approaches. The multicentre randomised phase II LEGEND trial evaluated lenalidomide in combination with rituximab, methylprednisolone and gemcitabine (R-GEM-L) vs. standard R-GEM-P as second-line treatment of DLBCL. The study closed early to recruitment after the planned interim analysis failed to demonstrate a complete response (CR) rate of ³ 40% in either arm. Among 34 evaluable patients, 7/18 (38.9%) achieved CR with R-GEM-L and 3/16 (18.8%) with R-GEM-P. Median event-free and overall survival was 3.5/3.8 months and 10.8/8.3 months for R-GEM-L and R-GEM-P, respectively. The incidence of grade ³ 3 toxicities was 52% in R-GEM-L and 83% in R-GEM-P. Efficacy and tolerability of R-GEM-L seem comparable with R-GEM-P and other standard salvage therapies, but a stringent design led to early trial closure. Combination of lenalidomide with gemcitabine-based regimens should be further evaluated in r/r DLBCL.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s00277-019-03842-4en
dc.titleR-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialen
dc.typeArticleen
dc.contributor.departmentRoyal Marsden NHS Foundation Trust London and Surrey, Downs Road Sutton, Surreyen
dc.identifier.journalAnnals of Hematologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record